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classified according to the first drug dispensing during 6 months from the discharge 
date. Patients were categorized in low ischemic stroke (CHA2DS2-VASc) (LR, score= 0), 
moderate-risk (MR, score= 1), high-risk (HR, score≥ 2).Multivariable logistic regression 
was used to evaluate the associations between ischemic stroke and bleeding (HAS-
BLED) risk with the choice of non-vitamin K antagonist oral anticoagulants (NOACs) 
versus vitamin K antagonists (VKAs) therapy. Results: A total of 1,963 patients were 
identified: 4.9% LR, 7.6% MR and 87.5% HR patients. Overall, 36.4% of patients were 
not treated (LR: 56.7%, MR: 55.0%, HR: 33.7%patients). Among patients treated, VKA in 
monotherapy was prescribed to 26.7% of the patients (LR: 23.8%, MR: 26.9%, HR: 26.8%), 
aspirin in monotherapy to 27.5% (LR: 31.0%, MR: 34.3%, HR: 27.0%), NOAC in mono-
therapy to 19.3% (LR: 23.8%, MR: 17.9%, HR: 19.2%), other antiplatelet in monotherapy 
to 19.4% (LR: 16.7%, MR: 13,4%, HR: 19.8%), and associations to 7.1% (LR: 4.8%, MR: 
7.5%, HR: 7.2%). The ischemic stroke and bleeding risks were not significantly associ-
ated with the choice of anticoagulant drug. ConClusions: High proportion of NVAF 
patients with moderate or high stroke risk did not receive antithrombotic therapy 
as recommended by guidelines. Moreover, aspirin was commonly prescribed even in 
HR patients. The risk stratification did not influence the choice of anticoagulant drug.
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objeCtives: The aim of this study was to assess the prevalence and characteristics 
of subjects with a recent ACS episode (in the year preceding statin prescription) 
appropriately treated with high-efficacy statins, and who have inadequate control of 
LDL-C levels, despite being adherent to treatment Methods: An observational ret-
rospective cohort analysis based on five Local Health Units administrative databases 
was conducted, for a total number of 1.2 Million beneficiaries. Patients who have 
been hospitalized with ICD9 code 410 in the year preceding their first statin pre-
scription (between January 1, 2011 and December 31, 2012) were included. Patients 
were characterized back 12 months from index date to assess appropriateness and 
adherence to statin treatment Results: Among patients with recent ACS enrolled 
(1’098 patients), 549 (50%) had no LDL-C determination, 335 (31%) and 214 (19%) 
displayed LDL-C under control and out of control, respectively. Among patients 
with uncontrolled LDL-C, 16 (7%) and 198 (93%) were not treated and treated with 
statins, respectively. Among patients with statins treatment, 27 (14%) and 171 (86%) 
were treated with low and high efficacy statins, respectively. Finally, among patients 
treated with high efficacy statins, 115 (67%) and 56 (33%) were non-adherent and 
adherent to high efficacy statin treatment, respectively. LDL-C uncontrolled high 
efficacy adherent patients showed different distances from their lipid target: 33.9% 
were less than 10% distant, 16.1% were 10-19% distant, 14.3% were 20-29% distant, 
12.5% were 30-39% distant and 23.2% were more than 40% distant ConClusions: 
These results are topical, as new monoclonal antibodies are being marketed to 
address the unmet need in cholesterol statin-management of dyslipidaemia for 
uncontrolled patients. By projecting study percentages to the Italian population, 
the number of LDL-C measured patients with a recent ACS episode who are uncon-
trolled, despite being adherent to a high efficacy statin, would be around 6’524
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objeCtives: In Japan, real-world evidence regarding impact of obesity on the preva-
lence of hypertension is lacking. The objective of this study was to investigate the 
prevalence and treatment status of hypertension in obese patients, with a focus on 
resistant hypertension. Methods: This was a retrospective study using a Japanese 
healthcare database composed of annual health checkup and claims data (MinaCare 
Co. Ltd.). Subjects aged > = 20 years at 2012 health checkup with 2 years (2011/2012) of 
checkups were selected for the study. Diagnosed hypertensive subjects (ICD-10 codes 
I10-I15) who were prescribed with antihypertensive medications within 1 year prior to 
checkup were defined as “treated”. Resistant hypertension was defined as uncontrolled 
hypertension (SBP/DBP> = 140/90mmHg) with 3 classes of antihypertensives including 
diuretics, or the use of > = 4 classes. Results: A total of 462,323 subjects (32% female, 
68% male) were analyzed. The age category 40-< 50 years accounted for the largest 
proportion (35%) of the sample. The mean BMI was 21.8/23.7 and the proportion of 
obese subjects (BMI> = 25) was 16.0%/29.9% (female/male). Approximately 10.4% of the 
subjects were “treated”. For each age, sex, and treatment category, the prevalence of 
hypertension (defined as SBP/DBP> = 140/90mmHg or “treated”) increased with increas-
ing BMI. In particular, males in 40-< 50 age category, odds-ratio for the prevalence of 
hypertension versus BMI 18.5-< 25 were 0.601, 3.607, 7.405, 15.445 for BMI categories 
< 18.5, 25-< 30, 30-< 35, 35-< 40, 40-, respectively. The prevalence of resistant hyperten-
sion among those diagnosed and prescribed with antihypertensives was consistently 
higher for obese subjects (vs non-obese) for each sex and age category; in particular, it 
was 4.1% (obese) vs 8.7% (non-obese) for males in 40-< 50 age category. ConClusions: 
We demonstrated that prevalence of resistant hypertension as well as that of hyper-
tension increased with increasing BMI using healthcare database in Japan. These 
results reconfirm the impact of obesity in the treatment and control of hypertension.
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objeCtives: The aim of this study was to assess the prevalence and character-
istics of subjects appropriately treated with high-efficacy statins, and who have 
and iloprost were 31% to 22% and 26% to 10%, respectively. Use of other PAH-specific 
medication among PGI2 users increased over time, from 62% in CY2010 to 69% in 
CY2014. Mean (standard deviation [SD]) annualized PGI2 costs ranged from $99,919 
($100,139) to $118,861 ($136,493) per CY. Use of parenteral PGI2 decreased over time 
(from 63.2% in CY2010 to 52.4% in CY2014), whereas non-parenteral PGI2 usage 
increased (from 39.7% to 49.5%). Other PAH-specific medications were used in the 
same CY for 74.1%–77.6% of non-parenteral PGI2 users, compared to 54.4%–64.3% 
of parenteral PGI2 users. Mean parenteral PGI2 costs in CY2010 were twice those 
of non-parenteral PGI2. By CY2014, parenteral PGI2 costs were 8% lower than non-
parenteral costs. Mean (SD) PAH-related costs ranged from $189,763 ($167,329) dur-
ing CY2010 to $199,336 ($194,638) during CY2013. ConClusions: While overall use 
of PGI2 was constant over the five-year period, our findings suggest a shift towards 
non-parenteral PGI2 and PGI2 combination therapy in clinical practice.
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objeCtives: Hypertension is one of the major risk factors for occurrence cardiovas-
cular disease. Drugs of the first choice in the treatment of hypertension are: diuretics, 
beta adrenergic blockers, calcium channel blockers, angiotensin converting enzyme 
inhibitors and inhibitors of angiotensin II receptor. Fixed combinations of antihyper-
tensive drugs simplify treatment and enhance patient compliance. The aim of this 
study was to analyze consumption fixed combinations of drugs for the treatment of 
hypertension in the Republic of Serbia in the 2011-2012 year and to compared it with 
the results of Finland and Norway in the same period. Methods: Consumption of 
officinals is expressed by the number of defined daily doses per 1000 inhabitants per 
day (DDD) according to the anatomical therapeutic chemical classification. Data on 
consumption of drugs are taken from the official web site for the period 2007– 2012. 
year from the Agency for drugs and medical devices of Serbia, Finnish Medicines 
Agency Fima and Norwegian Institute of Public Health. Results:: Fixed combina-
tion of converting enzyme inhibitors with diuretics are most frequently used drugs 
in Serbia (2007 (18,86 DDD), 2008 (26,61 DDD), 2009 (30,77 DDD), 2010 (27,30 DDD), 2011 
(43,72 DDD) and 2012 (55,52 DDD)) compared with Norway and Finland. The use of 
these drugs is on the rise in Serbia. In the opposite side use of angiotensin II antago-
nists and diuretics in Serbia is significantly lower (2007 (0,10 DDD), 2008 (0,07 DDD), 
2009 (0,12 DDD), 2010 (0,19 DDD), 2011 (0,73 DDD) and 2012 (1,70 DDD)) compared with 
Norway and Finland. ConClusions: Based on the results, we concluded that the use 
of fixed combination of drugs in therapy of hypertension in Serbia must be modified. 
This research was supported by Provincial Secretariat for Science and Technological 
Development, Autonomous Province of Vojvodina project No 114-451-2458/2011 and 
by Ministry of Science, Republic of Serbia, project no 41012
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objeCtives: To assess, in a community setting, the clinical and economic outcomes 
of individuals with diabetes at very high cardiovascular (CV) risk (patients with type 
2 or type 1 diabetes, with target organ damage, such as microalbuminuria - ESC/
EAS Guidelines 2011). Methods: Data for over 2.9 million subjects were extracted 
from 6 Local Health Units (ARNO Observatory, an administrative database containing 
data on hospitalizations, prescriptions and diagnostic/outpatient visits). The index 
period lasted from January 1 to December 31, 2011. Results: Of the 2,989,512 sub-
jects identified, 101,217 patients (3.4%) had diabetes with very high CV risk. 82.9% 
were aged over 60 years. At 1-year follow-up, 46.1% were prescribed statin therapy, 
of which 56.9% being prescribed high intensity statins (Atorvastatin 40, 80 mg/dL, 
Rosuvastatin 20, 40 mg/dL). Adherence to treatment (20% tolerability in one year 
follow-up treatment - CORE Study 2013) was higher among high intensity statin users 
compared to low intensity statin users (53.6% vs 40.1%). Over the 1-year follow-up 
period, 23,116 patients (22.8%) were hospitalized for any CV events. The average 
yearly cost per patient, on the high risk diabetic patients, supported by NHS was 
3,001 € /year (hospitalizations: 1,555€ ; drugs: 998€ ; diagnostic and outpatient vis-
its: 449€ ). ConClusions: In this community hospital setting, diabetic patients at 
very high risk of CV were frequently hospitalized for CV events. Although at high 
risk, less than 50% of patients was prescribed on statin therapy and adherence was 
suboptimal. Individuals with diabetes at very high CV risk utilize a significant por-
tion of economic resources, hospitalization being the main cost driver. Local Health 
Authorities together with Physicians and Patient Associations are working to close 
the gap between the existing evidence-based recommendations and current clinical 
practice which could result in a reduction of both diabetes morbidity and health cost.
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objeCtives: To assess the level of adherence to the guidelines for the preven-
tion of thromboembolic risk in patients with Non-Valvular Atrial Fibrillation 
(NVAF). Methods: A population-based cohort study was conducted using admin-
istrative data from a local health authority in the Campania Region (~1,000,000 
inhabitants). NVAF was defined as one or more claims for atrial fibrillation (ICD-
9-CM code 427.31) between July, 2013 and June, 2014 where none of the claims were 
associated with cardioversion or cardiac ablation during the identification period 
and there was no evidence of valve-related diagnoses or procedures. The cohort was 
